Curis may proceed with CUDC-427 trial


The FDA completes its review of Curis' (CRIS) CRL response to the partial clinical hold on its anti-cancer agent CUDC-427. The agency determines that it is safe to proceed.

The phase 1 study on patients with solid tumors was placed on partial clinical hold in November after one patient died due to liver failure one month after discontinuing the drug. No new patients could be enrolled until Curis submitted data and analyses on all treated patients plus a protocol amendment.

Shares are up 17% premarket on light volume.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs